Glucotrack plans US trial of implantable glucose monitor this year

Glucotrack plans US trial of implantable glucose monitor this year

Glucotrack plans to file for an investigational device exemption in the second quarter, with hopes of starting a trial in the second half of 2026.

Glucotrack to Submit IDE Application to FDA in Early Q2

Glucotrack, a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today provided a comprehensive recap of the critical operational milestones which have positioned the Company to submit an IDE to the U.S. Food and Drug Administration (FDA) for its novel continuous blood glucose monitoring (CBGM) technology, with a goal to file requisite documents with the FDA during…

GlucoTrack Targets Mid-2026 FDA Filing for Next-Gen Glucose Monitoring Technology; Stock Soars

GlucoTrack (NASDAQ: GCTK) has outlined plans to pursue U.S. regulatory clearance for its glucose monitoring device, a development that quickly boosted investor sentiment. Specifically, the company announced it intends to submit an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) in the second quarter of 2026. Following this update, the market reacted quickly. Shares climbed over 30% in pre-market …

Glucotrack to submit CBGM for FDA IDE in early Q2

Glucotrack 3-year continuous blood glucose monitor (CBGM) Glucotrack (Nasdaq:GCTK) today provided an update on the planned regulatory timeline for its continuous blood glucose monitor (CBGM). The Glucotrack device features no on-body external component. The company designed it for three years of continuous, accurate blood glucose monitoring for a more convenient, less intrusive solution. Unlike traditional CGMs that measure glucose in interstiti…